Biotechnology · NASDAQ
当前价格
$317.36
内在价值
使用下方计算器估算
对 Alnylam Pharmaceuticals, Inc. 运行 PE 市盈率估值,自动填充盈利数据,可调节目标 PE,即时获得公允价值估算。
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Earnings Yield
0.75%
ROE (TTM)
90.3%
基于过去 12 个月的数据,ALNY 每股收益为 N/A,市盈率为 N/A。 这些是使用 PE 市盈率方法进行股票估值的关键输入。
ALNY 的过去 12 个月市盈率反映投资者为 Alnylam Pharmaceuticals, Inc. 每一美元收益所支付的价格。该指标在与Biotechnology同类公司和公司自身历史区间对比时最有意义。
ALNY 是否被高估取决于将其市盈率与Biotechnology同类公司、历史均值和增长预期比较。高于行业均值的 PE 可能暗示高估,但高增长公司通常有更高的估值倍数。建议配合 DCF 模型获得更完整的判断。
对 Alnylam Pharmaceuticals, Inc. 使用 PE 估值的步骤:(1) 将当前市盈率与Biotechnology中位数对比评估相对定价,(2) 查看 PEG 比率以调整增长预期,(3) 参考 5 年 PE 历史区间判断当前位置,(4) 用目标 PE 乘以前瞻 EPS 估算公允价值。这种相对估值方法与 DCF 的绝对估值互为补充。
PEG 比率将市盈率除以预期盈利增速,提供增长调整后的估值指标。PEG 低于 1.0 可能表明相对于增长被低估,高于 2.0 可能暗示高估。PEG 对盈利增长稳定可预测的公司最为可靠。
PE 市盈率给出快速的相对定价——ALNY 相对于Biotechnology同类的估值水平。DCF 基于预期自由现金流提供绝对价值。对于 ALNY,ROE 达到 90.3%,两种方法都值得使用——PE 做市场对比,DCF 验证基本面是否支撑当前价格。两种方法各有盲区:PE 忽略了资本结构和现金流质量,DCF 则对增长率和折现率假设非常敏感。